Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388604 | 0.82 | CYP2D6 (0.36) | HRH3CYP2D6 | |
| SCHEMBL4394004 | 0.75 | HRH3 (0.34) | HRH3CYP2D6ALDH1A1 | |
| SCHEMBL4387828 | 0.75 | L3MBTL3 (0.38) | HRH3CYP2D6CYP3A4CYP2C19L3MBTL3 | |
| SCHEMBL4387949 | 0.74 | DPP7 (0.55) | ALDH1A1SIGMAR1L3MBTL3MBTD1L3MBTL1 | |
| SCHEMBL8263855 | 0.73 | L3MBTL3 (0.47) | HRH3CYP2D6CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL278657 | 0.73 | L3MBTL3 (0.47) | HRH3CYP2D6CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL8255448 | 0.73 | L3MBTL3 (0.47) | HRH3CYP2D6CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL4382950 | 0.72 | ALDH1A1 (0.42) | HRH3CYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL8259607 | 0.72 | L3MBTL3 (0.46) | HRH3CYP2D6CYP2C19ALDH1A1L3MBTL3 | |
| SCHEMBL3439846 | 0.72 | L3MBTL3 (0.48) | HRH3CYP2D6CYP2C19L3MBTL3MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | HRH3 452/4885CYP2D6 1166/4885CYP3A4 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.